2cureX

CEO Nat Hutley comments:
“EXECUTION. EXPANSION. ACCELERATION.

2024 was the year 2cureX transformed. The first half of 2025 proved that our new strategy is not just vision — it is working.

We have validated our Direct-to-Patient model, connected to the pharmaceutical industry through our PreComb partnership, and positioned IndiTreat® at the center of a fast-emerging precision oncology market. Patients are engaging. Pharma is preparing trials. Investors are leaning in.

We are running this company differently. By embedding AI into our workflows, we are building a lean, fast, and scalable organization. Every euro raised is being amplified by automation, enabling us to move at a pace rarely seen in healthcare.

Our partner, 2cureX A/S, is on track to deliver full CE-IVDR approval later this year, unlocking access to wider healthcare adoption and reimbursement. With IndiTreat® expanding into new cancer indications, the commercial opportunity continues to grow.

The market is also speaking. Strong transactions like CELLphenomics €44 million acquisition by GSK underline investor appetite after similar acquisitions have been made by Merrik, Tempus and others. 2cureX is uniquely placed to benefit — with real patients, real trials, and real momentum.

Looking forward, our priorities are bold and focused:

• Expand Direct-to-Patient access across Europe’s largest healthcare systems.
• Execute on PreComb’s pharma-driven clinical trials in multiple indications.
• Support 2cureX A/S in securing IVDR approvals.
• Integrate AI and automation across our operations for speed and efficiency.
• Attract Tier-1 leadership talent to take 2cureX to the next level.
• Pursue acquisitions that consolidate our leadership in functional precision oncology.

Highligts and key figures

H2 2024 has been defined by execution, validation, and expansion. With a lean AI-powered operation, strong partnerships, and unwavering investor support, 2cureX is rapidly scaling into Europe’s leading precision oncology platform.”

First half year of 2025 (2025-01-01 until 2025-06-30):

The result before tax was -1 951 KSEK (-9 560 KSEK)
The result per share* was -0.78 SEK (-0.54 SEK)
The solidity** was 12 % (40 %).
The cash and bank were 5 098 KSEK (3 130 KSEK).